Furthermore, CD19-resistant NHL cells showing no aberrant loss of CD19 antigen could be sensitized to subsequent CAR therapy and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) apoptotic pathway upon SAHA and Celecoxib treatment. Here, CD19 is linked to non-Hodgkin lymphoma.